Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 13/20 | 0.40 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.39 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26504187 | 0.82 | HCRTR1 (0.31) | EPAS1HCRTR1HCRTR2 | |
| SCHEMBL30054485 | 0.75 | UGT2B17 (0.47) | EPAS1VEGFACYP11B1CYP11B2PGR | |
| SCHEMBL23846911 | 0.72 | — | — | |
| SCHEMBL31737139 | 0.70 | EPAS1 (0.44) | EPAS1VEGFA | |
| SCHEMBL23832875 | 0.69 | KDM4E (0.38) | CYP11B2PGR | |
| SCHEMBL30054919 | 0.69 | KDM4E (0.38) | CYP11B2PGR | |
| SCHEMBL30054577 | 0.69 | EPAS1 (0.36) | EPAS1CYP11B1CYP11B2 | |
| SCHEMBL25168135 | 0.66 | PGR (0.41) | EPAS1CYP11B1CYP11B2PGR | |
| SCHEMBL22143614 | 0.65 | IDO1 (0.39) | EPAS1VEGFACYP11B1CYP11B2 | |
| SCHEMBL8612191 | 0.65 | IDO1 (0.39) | EPAS1VEGFACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2021188769-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | HIF1AN, HIF1A, EGLN2 | EPAS1 8/4885ELAVL1 1732/4885POLL 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.